Senti Biosciences to spin off SENTI-202 assets to Celadon-backed NewCo for CVR worth up to $60 million
PUBT · 7h ago
Share
Listen to the news
- Celadon-controlled NewCo to acquire Senti Biosciences Holdings’ Gene-Circuit pipeline assets, including rights to AML therapy SENTI-202.
- Consideration is a contingent value right distributed to equity holders, offering up to USD 60 million in milestones over seven years.
- Milestones: USD 10 million on BLA filing and acceptance, USD 20 million on FDA approval, USD 30 million at USD 200 million cumulative net sales.
- Senti Biosciences Holdings to retain the Regulator Dial platform, pivoting to controllable genetic medicines and seeking additional financing to fund early-stage programs.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Senti Biosciences Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607150730PRIMZONEFULLFEED9762395) on July 15, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved